Adimmune Statistics

Total Valuation

Adimmune has a market cap or net worth of TWD 9.27 billion. The enterprise value is 10.40 billion.

Market Cap	9.27B
Enterprise Value	10.40B

Important Dates

The next estimated earnings date is Friday, March 28, 2025.

Earnings Date	Mar 28, 2025
Ex-Dividend Date	n/a

Share Statistics

Adimmune has 421.51 million shares outstanding. The number of shares has decreased by -0.15% in one year.

Current Share Class	n/a
Shares Outstanding	421.51M
Shares Change (YoY)	-0.15%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	1.02%
Owned by Institutions (%)	2.91%
Float	314.38M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	5.90
PB Ratio	1.75
P/TBV Ratio	1.77
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-17.09
EV / Sales	6.62
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-28.71

Financial Position

The company has a current ratio of 3.28, with a Debt / Equity ratio of 0.47.

Current Ratio	3.28
Quick Ratio	2.27
Debt / Equity	0.47
Debt / EBITDA	n/a
Debt / FCF	-7.26
Interest Coverage	-16.02

Financial Efficiency

Return on equity (ROE) is -12.24% and return on invested capital (ROIC) is -4.37%.

Return on Equity (ROE)	-12.24%
Return on Assets (ROA)	-4.21%
Return on Capital (ROIC)	-4.37%
Revenue Per Employee	2.79M
Profits Per Employee	-1.08M
Employee Count	564
Asset Turnover	0.18
Inventory Turnover	1.19

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -29.15% in the last 52 weeks. The beta is 0.52, so Adimmune's price volatility has been lower than the market average.

Beta (5Y)	0.52
52-Week Price Change	-29.15%
50-Day Moving Average	21.39
200-Day Moving Average	25.85
Relative Strength Index (RSI)	49.37
Average Volume (20 Days)	9,429,979

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Adimmune had revenue of TWD 1.57 billion and -608.33 million in losses. Loss per share was -1.44.

Revenue	1.57B
Gross Profit	416.22M
Operating Income	-602.44M
Pretax Income	-727.29M
Net Income	-608.33M
EBITDA	-414.67M
EBIT	-602.44M
Loss Per Share	-1.44

Full Income Statement

Balance Sheet

The company has 1.85 billion in cash and 2.63 billion in debt, giving a net cash position of -779.27 million or -1.85 per share.

Cash & Cash Equivalents	1.85B
Total Debt	2.63B
Net Cash	-779.27M
Net Cash Per Share	-1.85
Equity (Book Value)	5.64B
Book Value Per Share	12.57
Working Capital	2.60B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -89.29 million and capital expenditures -272.91 million, giving a free cash flow of -362.20 million.

Operating Cash Flow	-89.29M
Capital Expenditures	-272.91M
Free Cash Flow	-362.20M
FCF Per Share	-0.86

Full Cash Flow Statement

Margins

Gross margin is 26.49%, with operating and profit margins of -38.34% and -38.71%.

Gross Margin	26.49%
Operating Margin	-38.34%
Pretax Margin	-46.28%
Profit Margin	-38.71%
EBITDA Margin	-26.39%
EBIT Margin	-38.34%
FCF Margin	n/a

Dividends & Yields

Adimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	0.15%
Shareholder Yield	0.15%
Earnings Yield	-6.56%
FCF Yield	-3.91%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Adimmune has an Altman Z-Score of 2.89. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.89
Piotroski F-Score	n/a